Please assess the completion status of the following clinical trial:

Trial Title: Metformin for the Treatment of Premature Pubarche in Girls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Girls aged 4-10 with pubic hair prior to 8 years of age~2. Elevated DHEAS level above age normal levels~3. Informed consent from parents and assent from the girl~Exclusion Criteria:~1. Diagnosis of incomplete precocious puberty, peripheral precocious puberty, or evidence of any abnormal pituitary, hypothalamic, adrenal, thyroid, and gonadal function other than premature secretion of adrenal androgens.~2. Chronic illness requiring treatment that may interfere with growth and development, i.e. chronic steroid use, renal failure, etc.~3. 21-hydroxylase deficiency or other enzyme deficiency leading to the phenotype of congenital adrenal hyperplasia. 21-hydroxylase deficiency will be excluded in all patients by a fasting 17-hydroxyprogesterone (17-OHP) level \< 2 ng/mL. In the case of elevated fasting 17-OHP levels, an ACTH stimulation test will be performed. A 1-hour stimulated value \> 10 ng/mL will be an exclusion 82. As 21 hydroxylase deficiency is a congenital condition, any normal level in the past of 17-hydroxyprogesterone allows entry into this study.~4. Uncorrected thyroid disease (defined as TSH \< 0.2 mIU/ML or \> 5.5 mIU/mL). A normal level within the last year is adequate for entry.~5. Type I or Type II diabetes (defined as a fasting serum glucose \> 125mg/dL on two occasions 83), or patients receiving anti-diabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas; patients currently receiving metformin XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically excluded.~6. Liver disease defined as AST or ALT \> 2 times normal or total bilirubin \> 2.5 mg/dL.~7. Renal disease defined as BUN \> 30 mg/dL or serum creatinine \> 1.4 mg/dL.~8. Significant anemia (Hemoglobin \< 10 mg/dL).~9. History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.~10. Known heart disease (New York Heart Association Class II or higher).~11. Enrolled simultaneously into other investigative studies that require medications, proscribe the study medications, or otherwise prevent compliance with the protocol. Patients who anticipate taking longer than a one month break during the protocol should not be enrolled.~12. Concomitant use other medications known to affect reproductive function or metabolism. These medications include growth hormone, IGF-1, medroxyprogesterone acetate, oral contraceptives, GnRH agonists and antagonists, anti-androgens, gonadotropins, anti-obesity drugs, somatostatin, diazoxide, ACE inhibitors, and calcium channel blockers. The washout period on all these medications will be three months.~13. Suspected adrenal or ovarian tumor secreting androgens or other ectopic steroid secreting tumor.~14. Suspected Cushing's syndrome.~15. Lactose intolerance (the placebo filler is lactose).~16. Known hypersensitivity to study medication, including ACTH and GnRH, or their excipients.~17. Any concomitant medical condition that in the opinion of the investigator, may expose a subject to unacceptable level of safety risk, or that affects subject compliance.~18. Subjects who anticipate having any surgery associated with restricted intake of fluids or radiological studies with contrast dye during the study period.~19. Any concomitant medical condition that in the opinion of the investigator, may expose a subject to unacceptable level of safety risk, or that affects subject compliance.

- Gender: FEMALE
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- sugar pill (Type: PLACEBO_COMPARATOR): 2 pills per day for 12 months
- Metformin (Type: ACTIVE_COMPARATOR): 2 212.5mg pill/day for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).